SFI
BCRX icon

Susquehanna Fundamental Investments’s BioCryst Pharmaceuticals BCRX Stock Holding History

Susquehanna Fundamental Investments’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-96,288
Closed -$722K – 748
2025
Q1 		$722K Buy
96,288
+7,434
+8% +$60K 0.01% 764
2024
Q4 		$668K Buy
+88,854
New +$675K 0.01% 804
2024
Q2 		$186K Sell
30,176
-34,189
-53% -$189K ﹤0.01% 854
2024
Q1 		$327K Buy
+64,365
New +$362K 0.02% 538

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Susquehanna Fundamental Investments's BCRX Position: Q2 2025 in Review

Susquehanna Fundamental Investments sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2025, closing a stake of 96,288 shares — an estimated $722K sold.

Susquehanna Fundamental Investments first reported a position in BCRX in Q1 2024 and held it in 4 quarters. The position peaked at $722K in Q1 2025. 294 funds tracked by Wall St. Rank hold BCRX as of Q2 2025.

  • Susquehanna Fundamental Investments reported no remaining BioCryst Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 96,288 BioCryst Pharmaceuticals shares in Q2 2025, an estimated $722K.
  • Susquehanna Fundamental Investments first reported a position in BioCryst Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • Susquehanna Fundamental Investments's BioCryst Pharmaceuticals position peaked at $722K in Q1 2025.
  • 294 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2025, filed 14 Aug 2025.